Tempest Therapeutics’ Oncology Programs Presented at Society of Immunotherapy for Cancer Annual Meeting
November 08, 2019 08:00 ET
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage biotechnology company developing a broad portfolio of first-in-class small molecule...
Tempest Therapeutics Names Biopharmaceutical Executive Stephen Brady as President and Chief Operating Officer
October 07, 2019 08:00 ET
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage biotechnology company developing a diverse portfolio of first-in-class small molecules...
Tempest Therapeutics Announces Multiple Presentations at Upcoming SITC 34th Annual Meeting
October 02, 2019 16:00 ET
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage biotechnology company developing a broad portfolio of first-in-class small molecules...